ZIVO Bioscience Announces Pricing Of $4M Registered Direct Offering
Portfolio Pulse from Benzinga Newsdesk
ZIVO Bioscience has announced the pricing of a $4 million registered direct offering. The company plans to use the proceeds for general corporate purposes.

June 30, 2023 | 5:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ZIVO Bioscience's $4M registered direct offering could potentially dilute existing shareholders' equity, but also provide the company with additional capital for corporate purposes.
The announcement of a registered direct offering often has a mixed impact on a company's stock. On one hand, it can lead to dilution of existing shareholders' equity, which can negatively impact the stock price. On the other hand, it provides the company with additional capital that can be used for various corporate purposes, which could potentially have a positive impact on the company's future performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100